Departments of Psychiatry, University of KwaZulu-Natal, Durban, South Africa
Departments of Psychiatry, University of KwaZulu-Natal, Durban, South Africa.
BMJ Open. 2022 Feb 22;12(2):e052903. doi: 10.1136/bmjopen-2021-052903.
Untreated post-traumatic stress disorder (PTSD) results in considerable morbidity and higher risk of mortality. However, little is being done to treat PTSD in sub-Saharan Africa (SSA) settings where rates of PTSD are likely to be elevated due to mass exposure of the population to traumatic events. This systematic review aims to summarise available evidence on the efficacy of psychological therapies for PTSD in SSA.
A systematic search of the literature will be conducted in four electronic databases: PubMed, PsychInfo, EMBASE and Cochrane Register of Controlled Trials using keywords and synonyms related to 'PTSD', 'psychological therapies' and 'SSA'. Studies will be included if they were conducted in SSA and used a randomised controlled trial design. Two researchers will screen the studies for eligibility to be included, and data on intervention types, population, comorbidities, comparison group intervention and PTSD outcomes will be extracted from those included. Risk of bias will be assessed using Cochrane risk-of-bias tool for randomised trials (version 2). Narrative synthesis of data will be conducted and pooled effect estimates calculated.
Ethical approval is not required as this is a protocol of a systematic review of available data. Findings will be disseminated to the scientific community through peer-reviewed publications and presentation at conferences.
CRD42020181638.
未经治疗的创伤后应激障碍（PTSD）会导致相当大的发病率和更高的死亡率。然而，在撒哈拉以南非洲（SSA）地区，几乎没有采取任何措施来治疗 PTSD，因为该地区的人口可能因大规模接触创伤事件而导致 PTSD 发病率升高。本系统评价旨在总结有关 SSA 地区 PTSD 的心理疗法疗效的现有证据。
将使用与“创伤后应激障碍”、“心理疗法”和“SSA”相关的关键词和同义词，在四个电子数据库中进行文献系统检索：PubMed、PsychInfo、EMBASE 和 Cochrane 对照试验登记处。如果研究在 SSA 进行且采用随机对照试验设计，则将其纳入研究。两名研究人员将筛选符合纳入标准的研究，并从纳入的研究中提取干预类型、人群、合并症、对照组干预和 PTSD 结局的数据。将使用 Cochrane 随机试验偏倚风险工具（版本 2）评估偏倚风险。将对数据进行叙述性综合，并计算合并效应估计值。
由于这是对现有数据进行系统评价的方案，因此不需要伦理批准。研究结果将通过同行评议的出版物和会议报告向科学界传播。
PROSPERO 注册号：CRD42020181638。
